- Home
- PCRX vs UWMC Comparison
PCRX vs UWMC Comparison
Compare PCRX & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- UWMC
- Stock Information
- Founded
- PCRX 2006
- UWMC 1986
- Country
- PCRX United States
- UWMC United States
- Employees
- PCRX N/A
- UWMC N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- UWMC Finance: Consumer Services
- Sector
- PCRX Health Care
- UWMC Finance
- Exchange
- PCRX Nasdaq
- UWMC Nasdaq
- Market Cap
- PCRX 1.2B
- UWMC 1.4B
- IPO Year
- PCRX 2011
- UWMC N/A
- Fundamental
- Price
- PCRX $21.85
- UWMC $5.66
- Analyst Decision
- PCRX Buy
- UWMC Hold
- Analyst Count
- PCRX 5
- UWMC 8
- Target Price
- PCRX $32.40
- UWMC $6.46
- AVG Volume (30 Days)
- PCRX 577.9K
- UWMC 9.1M
- Earning Date
- PCRX 11-06-2025
- UWMC 11-06-2025
- Dividend Yield
- PCRX N/A
- UWMC 7.07%
- EPS Growth
- PCRX N/A
- UWMC 112.84
- EPS
- PCRX N/A
- UWMC 0.07
- Revenue
- PCRX $705,848,000.00
- UWMC $2,622,828,000.00
- Revenue This Year
- PCRX $7.27
- UWMC $11.44
- Revenue Next Year
- PCRX $10.18
- UWMC $12.48
- P/E Ratio
- PCRX N/A
- UWMC $85.39
- Revenue Growth
- PCRX 2.25
- UWMC 13.45
- 52 Week Low
- PCRX $16.00
- UWMC $3.80
- 52 Week High
- PCRX $27.64
- UWMC $7.14
- Technical
- Relative Strength Index (RSI)
- PCRX 41.81
- UWMC 47.60
- Support Level
- PCRX $21.20
- UWMC $5.45
- Resistance Level
- PCRX $22.74
- UWMC $5.90
- Average True Range (ATR)
- PCRX 0.96
- UWMC 0.21
- MACD
- PCRX 0.14
- UWMC 0.02
- Stochastic Oscillator
- PCRX 59.08
- UWMC 57.97
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.